Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kineta, a biotechnology company focused on the development of immune modulating drugs for critical diseases, and RLB Holdings, an investment fund founded by Ray and Lydia Bartoszek, have formed a joint venture Kineta RLB, which will commercialize promising, high value compounds in selective disease areas with unmet medical needs.
Subscribe to our email newsletter
RLB Holdings managing partner and co-founder Lydia Bartoszek said: "The vision of Kineta-RLB is to progress the clinical development in high need areas with the hope of improving the access to important new medical treatments in areas where patients do not have appropriate treatment options."
Kineta RLB president Craig W Philips noted that this approach will allow us to broaden the lifecycle management of some of the key assets in the Kineta portfolio and increase the value of the copmpany’s development programs to the benefit of both patients and investors.
"Our initial focus will be autoimmune diseases, an area where there have been only incremental advances despite the enormous need of tens of thousands of children and adults in the US and abroad," Philips added.